Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2).

Autor: Sackeim HA; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, USA. Electronic address: has1@columbia.edu., Aaronson ST; Sheppard Pratt Health System and Department of Psychiatry, University of Maryland, Baltimore, MD, USA., Bunker MT; LivaNova PLC, Houston, TX, USA., Conway CR; Department of Psychiatry, Washington University, St. Louis, MO, USA., George MS; Departments of Psychiatry,Neurology,and Neuroscience, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, USA., McAlister-Williams RH; Northern Centre for Mood Disorders, Translational and Clinical Research Institute, Newcastle University, UK; Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK., Prudic J; New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY, USA., Thase ME; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA., Young AH; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, UK., Rush AJ; Duke-NUS Medical School, Singapore; Duke University, Durham, NC, USA; Texas Tech University, Permian Basin, TX, USA.
Jazyk: angličtina
Zdroj: Journal of psychiatric research [J Psychiatr Res] 2024 Aug; Vol. 176, pp. 325-337. Date of Electronic Publication: 2024 Jun 12.
DOI: 10.1016/j.jpsychires.2024.05.046
Abstrakt: All definitions of treatment-resistant depression (TRD) require that patients have experienced insufficient benefit from one or more adequate antidepressant trials. Thus, identifying "failed, adequate trials" is key to the assessment of TRD. The Antidepressant Treatment History Form (ATHF) was one of the first and most widely used instruments that provided objective criteria in making these assessments. The original ATHF was updated in 2018 to the ATHF-SF, changing to a checklist format for scoring, and including specific pharmacotherapy, brain stimulation, and psychotherapy interventions as potentially adequate antidepressant treatments. The ATHF-SF2, presented here, is based on the consensus of the ATHF workgroup about the novel interventions introduced since the last revision and which should/should not be considered effective treatments for major depressive episodes. This document describes the rationale for these choices and, for each intervention, the minimal criteria for determining the adequacy of treatment administration. The Supplementary Material that accompanies this article provide the Scoring Checklist, Data Collection Forms (current episode and composite of previous episodes), and Instruction Manual for the ATHF-SF2.
Competing Interests: Declaration of competing interest Dr Harold A. Sackeim serves as a scientific adviser and receives consulting fees from Cerebral Therapeutics Inc., Holmusk Technologies Inc, LivaNovaPLC, MECTA Corporation, Neurolief Ltd, Neuronetics Inc, Parow Entheobiosciences LLC, and SigmaStim LLC. He receives honoraria and royalties from Elsevier Inc and Oxford University Press. He is the inventor on non-remunerative US patents for Focal Electrically-Administered Seizure Therapy (FEAST), titration in the current domain in ECT, and the adjustment of current in ECT devices, each held by Balance Point LLC. He is also the originator of magnetic seizure therapy (MST). His effort in chairing this revision of the ATHF and drafting the ATHF-SF2 documents was partially supported by LivaNovaPLC. Dr. Scott T. Aaronson reports no conflicts of interest directly relating to this work. He does report a number of other relationships with commercial entities. He serves as a consultant to Compass Pathways, Genomind, LivaNovaPLC, Neuronetics Inc., and Sage Therapeutics. He has received research support from Compass Pathways. Dr. Mark Bunker reports no conflicts of interest directly relating to this work. He is a consultant to LivaNova, PLC. Dr. Charles R. Conway reports no conflicts of interest directly relating to this work. He has received research support from Bristol-Myers Squibb Co., Stanley Medical Research Institute, National Institute of Mental Health, NeoSync Inc., Cyberonics Inc., Taylor Family Institute for Innovative Psychiatric Research, August Busch IV Foundation, and Barnes-Jewish Hospital Foundation. He previously served as a speaker for Bristol-Myers Squibb Co. and Otsuka Pharmaceuticals Co. He currently serves as a paid consultant to LivaNova PLC in designing studies involving vagus nerve stimulation. Dr. Mark S. George reports no conflicts of interest directly relating to this work. He has no equity ownership in any device or pharmaceutical company. He does occasionally consult with industry, although he has not accepted consulting fees from anyone who manufactures a TMS device, because of his role in NIH and DOD/VA studies evaluating this technology. His total industry related compensation per year is less than 10% of his total university salary. In the past two years, his industry involvement has included Brainsonix Corp. (unpaid consultant), Brainsway Ltd. (unpaid consultant, research grant, donated equipment), Cervel Neurotech Inc./NeoStim Inc. (unpaid consultant, research grant), LivaNovaPLC (consultant), MECTA Corp. (unpaid consultant, research grant), Microtransponder Inc. (DSMB member), Neuronetics Inc. (unpaid consultant, research grant, donated equipment), NeoSync (unpaid consultant, research grant), Nervive (unpaid consultant), Pure Tech Health Ventures (consultant). Dr. R. Hamish McAlister-Williams reports no conflicts of interest directly relating to this work. He has received fees from American Center for Psychiatry & Neurology United Arab Emirates, British Association for Psychopharmacology, European College of Neuropsychopharmacology, International Society for Affective Disorders, Janssen, LivaNova, Lundbeck, My Tomorrows, OCM Comunicaziona s.n.c., Pfizer, Qatar International Mental Health Conference, Sotherma, Sunovion, Syntropharma, UK Medical Research Council and Wiley; grant support from UK National Institute for Health Research Efficacy and Mechanism Evaluation Panel and Health Technology Assessment Panel; and non-financial support from COMPASS Pathways and Magstim. Dr. Joan Prudic reports no conflicts of interest. Dr. Michael E. Thase reports no conflicts of interest directly relating to this work. He does report a number of other relationships with commercial entities. During the past 3 years, he has been an advisory/consultant to Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Mocksha8, Nestlé (PamLab), Neuronetics, Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda. In addition to the National Institute of Mental Health, he received grant support from Acadia, the Agency for Healthcare Research and Quality, Alkermes, Assurex, Avanir, Forest Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceuticals, and Takeda. Dr. Thase received royalties from the American Psychiatric Press, Guilford Publications, Herald House and W.W. Norton & Company, Inc. Dr. Thase's spouse, Dr. Diane Sloan, works for Peloton Advantage, which did business with Pfizer and AstraZeneca. Dr Allan H. Young reports no conflicts of interest directly relating to this work. He has received payment for lectures and advisory boards for the following companies: Allegan, AstraZeneca, Bionomics, Boehringer Ingelheim, COMPASS, Eli Lilly, FlowNeuroscience, Janssen, LivaNova, Lundbeck, Neurocentrx, Noema Pharma, Novartis, Roche, Sage, Servier, Sumitomo Dainippon Pharma, and Sunovion, Takeda. He is a consultant to Johnson & Johnson and LivaNova. He has received honoraria for attending advisory boards and presenting talks at meetings organized by LivaNova. He is a Principal Investigator on studies funded by COMPASS, LivaNova, and Janssen, and Chief Investigator on a study funded by Novartis. He does not hold shares in pharmaceutical companies. Dr. A. John Rush reports no conflicts of interest directly relating to this work. He has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., Johnson and Johnson (Janssen), LivaNova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from LivaNova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. His effort in assisting in the drafting of this revision of the ATHF and associated ATHF-SF2 documents was partially supported by LivaNovaPLC.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: